D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
Chong-Xian Pan,Hongyong Zhang,Clifford G. Tepper,Tzu-yin Lin,Ryan R. Davis,James G. Keck,Paramita M. Ghosh,Parkash S. Gill,Susan D. Airhart,Carol J. Bult,David R. Gandara,Edison T. Liu,Ralph W deVere White +12 more
TL;DR: The PDX models described here show good correlation with the patient at the genomic level and known patient response to treatment, and supports further evaluation of the PDXs for their ability to accurately predict a patient’s response to new targeted and combination strategies for bladder cancer.
Journal ArticleDOI
Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved.
Peter F. Roberts,Michaela Straznicka,Primo N. Lara,Derrick H.M. Lau,David M. Follette,David R. Gandara,John R. Benfield +6 more
TL;DR: The current staging system is not prognostic for multifocal bronchioloalveolar carcinoma without lymph node metastases and consideration should be given to surgical resection when this tumor type is believed to be one of the cell types in multifocal disease without lymph nodes metastases.
Journal ArticleDOI
Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium.
Kim Margolin,Jeffrey Longmate,Timothy W. Synold,David R. Gandara,Jeffrey S. Weber,Rene Gonzalez,Mary Johansen,Robert A. Newman,Tracey Baratta,James H. Doroshow +9 more
TL;DR: Dolastatin-10 is unlikely to havesubstantial activity in the treatment ofmelanoma, and its pharmokinetics were evaluated in a subset of patients following courses 1 and 2, and no patient experienced an objective response.
Journal ArticleDOI
Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)
Angela M. Davies,Kari Chansky,Primo N. Lara,Paul H. Gumerlock,John Crowley,Kathy S. Albain,Stanley J. Vogel,David R. Gandara +7 more
TL;DR: Bortezomib plus gemcitabine/carboplatin resulted in a notable survival benefit in patients with advanced NSCLC, with the anticipated primary toxicity of myelosuppression.
Journal Article
SU5416 Plus Interferon α in Advanced Renal Cell Carcinoma: A Phase II California Cancer Consortium Study with Biological and Imaging Correlates of Angiogenesis Inhibition
Primo N. Lara,David I. Quinn,Kim Margolin,Frederick J. Meyers,Jeff Longmate,Paul Frankel,Philip C. Mack,Corinne Turrell,Peter E. Valk,Jyotsna U. Rao,Penelope Buckley,Theodore Wun,Robert C. Gosselin,Irina Galvin,Paul H. Gumerlock,Heinz-Josef Lenz,James H. Doroshow,David R. Gandara +17 more
TL;DR: Although SU5146 plus low-dose IFN exhibits biological activity in RCC as evidenced by significant declines in serial VEGF and plasminogen activator inhibitor-1 plasma levels, the 1-year EFS of 6% and adverse toxicity profile diminishes enthusiasm for additional studies with this combination in advanced RCC.